SAP001 for Gout
Trial Summary
What is the purpose of this trial?
This trial is testing SAP-001, a new oral medication, in adults with gout who haven't responded to standard treatments. The goal is to see if it can safely lower uric acid levels and reduce painful lumps caused by gout.
Will I have to stop taking my current medications?
The trial requires that you stop taking any medications known to lower uric acid levels, except for standard XOI therapies, at least 14 days before starting the trial. However, if you are taking losartan for blood pressure and have been on a stable dose for at least 6 months, you can continue using it.
Research Team
Carmen Arencibia
Principal Investigator
Study Official
Eligibility Criteria
Adults aged 18-65 with gout, BMI between 19 and 40, who have high uric acid levels despite taking standard gout medication (unless not suitable), can join this trial. They mustn't have chronic liver issues or recent use of certain uric acid-lowering drugs (except stable losartan users).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of three dosages of SAP-001 or placebo daily for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- SAP001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shanton Pharma Pte. Ltd.
Lead Sponsor
Shanton Pharma Co., Ltd.
Lead Sponsor